CompletedPHASE1, PHASE2NCT01845727

Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Ivan Dario Velez, Prof
PECET, Universidad de Antioquia, Medellin, Colombia
Intervention
Topical Amphotericin B at 3%(drug)
Enrollment
80 target
Eligibility
18-60 years · All sexes
Timeline
20142016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01845727 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials